| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 20th January 2021 | Fred E Cohen | 20,000 | Exercise of derivative | $13.78 | $275,600.00 |
| 30th December 2020 | Andrew Schiermeier | 1,500 | Exercise of derivative | $13.48 | $20,220.00 |
| 17th December 2020 | Perry A Karsen | 19,000 | Exercise of derivative | $15.78 | $299,820.00 |
| 17th December 2020 | Perry A Karsen | 19,000 | Exercise of derivative | $25.98 | $493,620.00 |
| 17th December 2020 | Perry A Karsen | 21,978 | Open or private sale | $52.52 | $1,154,284.56 |
| 17th December 2020 | Perry A Karsen | 19,000 | Exercise of derivative | $14.35 | $272,650.00 |
| 17th December 2020 | Perry A Karsen | 31,764 | Exercise of derivative | $18.00 | $571,752.00 |
| 17th December 2020 | Perry A Karsen | 45,450 | Open or private sale | $53.69 | $2,440,210.50 |
| 17th December 2020 | Perry A Karsen | 21,336 | Open or private sale | $54.33 | $1,159,184.88 |
| 1st December 2020 | Jose E Rivera | 5,000 | Exercise of derivative | $13.88 | $69,400.00 |
Intellia Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing.
Ticker: NTLA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1652130
Employees: 270
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $362 M (0%)
Marketable Securities, Current: $75 M (-66%)
Assets, Current: $446 M (54%)
Property, Plant and Equipment, Net: $16 M (-8%)
Other Assets, Noncurrent: $5 M (57%)
Assets: $491 M (46%)
Accounts Payable, Current: $7 Th (-99%)
Accrued Liabilities, Current: $15 M (0%)
Liabilities, Current: $59 M (65%)
Common Stock, Value, Issued: $6 Th (20%)
Common Stock, Shares, Issued: $59 M (16%)
Additional Paid in Capital, Common Stock: $717 M (25%)
Retained Earnings (Accumulated Deficit): $365 M (21%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $155 Th (-40%)
Stockholders' Equity (Parent): $352 M (0%)
Liabilities and Equity: $491 M (46%)
Revenue: $16 M (-44%)
Research and Development: $38 M (-47%)
General and Administrative Expenses: $12 M (-49%)
Operating Income/Loss: $33 M (-50%)
